Catalyst Wire Dossier Catalyst Wire Dossier

UthPeak NMNH (reduced nicotinamide mononucleotide)

reduced nicotinamide mononucleotide (NMNH) · EffePharm LTD
Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for UthPeak NMNH (reduced nicotinamide mononucleotide), covering 2025-07-04 to 2025-07-04. Get the full timeline:

Most recent: Clinical Trial Update: Evaluate the Safety, Tolerability, and Efficacy of UthPeak NMNH (Reduced Nicotinamide Mononucleotide) in Healthy Adult Participants [NA]

See pricing